A Phase 2 interventional study of CD1579 2.5% and CD1579 5% in Acne Vulgaris, sponsored by Galderma R&D. Completed at 6 sites in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-03-28.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing Benzoyl Peroxide in Acne Vulgaris — none open to participants now, 1 under way, none of them phase 3. Benzoyl Peroxide · Acne Vulgaris.
Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, this one is the 14th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 2, and was the 24th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 33 studies testing Benzoyl Peroxide in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
Benzoyl Peroxide: first FDA approval 1984 (BENZAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 236 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 90 across the 33 interventional studies. Of the 28 that completed or were terminated, 24 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 22nd largest by enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2014, is one of 5 in phase 2, and was the 31st registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to assess the efficacy and safety of two concentrations of CD1579 (2.5% and 5%) versus vehicle in the treatment of acne vulgaris in the Japanese patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benzoyl Peroxide 2.5%
Drug: CD1579 2.5%
Benzoyl Peroxide 5%
Drug: CD1579 5%
Vehicle
Drug: Vehicle
Also known as: Benzoyl Peroxide 2.5%
Also known as: Benzoyl Peroxide 5%
Percent Changes From Baseline in Total Lesion Counts
Median percent reductions from Baseline in total lesion count (ITT-LOCF)
Time frame: Baseline - Week 12
Percent of Subjects With Adverse Events
Adverse events which were observed in 5% or more patients with either group are listed.
Time frame: up to 12 weeks
Local Tolerability (Erythema)
Highest severity of local tolerability scores worse than Baseline
Time frame: 12 weeks
Local Tolerability (Scaling)
Highest severity of local tolerability scores worse than Baseline
Time frame: 12 weeks
Local Tolerability (Dryness)
Highest severity of local tolerability scores worse than Baseline
Time frame: 12 weeks
Local Tolerability (Pruritus)
Highest severity of local tolerability scores worse than Baseline
Time frame: 12 weeks
Local Tolerability (Stinging/Burning)
Highest severity of local tolerability scores worse than Baseline
Time frame: 12 weeks
| Milestone | CD1579 2.5% | CD1579 5% | Vehicle |
|---|---|---|---|
| Started | 79 | 78 | 79 |
| Completed | 75 | 77 | 78 |
| Not completed | 4 | 1 | 1 |
Median percent reductions from Baseline in total lesion count (ITT-LOCF)
| percent change | CD1579 2.5% | CD1579 5% | Vehicle |
|---|---|---|---|
| Percent Changes From Baseline in Total Lesion Counts | 58.3 (-243.7 to 100) | 65.9 (-41.0 to 100) | 25.5 (-180.7 to 88.9) |
Adverse events which were observed in 5% or more patients with either group are listed.
| percentage of participants | CD1579 2.5% | CD1579 5% | Vehicle |
|---|---|---|---|
| % of subjects with AEs | 43.0 | 39.7 | 32.9 |
| Nasopharyngitis | 12.7 | 14.1 | 13.9 |
| Headache | 10.1 | 1.3 | 8.9 |
| Dysmenorrhea | 6.3 | 3.8 | 3.8 |
Highest severity of local tolerability scores worse than Baseline
| participants | CD1579 2.5% | CD1579 5% | Vehicle |
|---|---|---|---|
| Mild | 12 | 18 | 5 |
| Moderate | 3 | 3 | 0 |
| Severe | 0 | 1 | 0 |
Highest severity of local tolerability scores worse than Baseline
| participants | CD1579 2.5% | CD1579 5% | Vehicle |
|---|---|---|---|
| Mild | 15 | 25 | 8 |
| Moderate | 4 | 7 | 1 |
Highest severity of local tolerability scores worse than Baseline
| participants | CD1579 2.5% | CD1579 5% | Vehicle |
|---|---|---|---|
| Mild | 20 | 33 | 10 |
| Moderate | 2 | 6 | 0 |
Highest severity of local tolerability scores worse than Baseline
| participants | CD1579 2.5% | CD1579 5% | Vehicle |
|---|---|---|---|
| Mild | 20 | 13 | 6 |
| Moderate | 6 | 7 | 1 |
| Severe | 1 | 2 | 0 |
Highest severity of local tolerability scores worse than Baseline
| participants | CD1579 2.5% | CD1579 5% | Vehicle |
|---|---|---|---|
| Mild | 19 | 29 | 4 |
| Moderate | 6 | 7 | 1 |
Collected over 12 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CD1579 2.5% | — | 0/79 (0%) | 34/79 (43%) |
| CD1579 5% | — | 0/78 (0%) | 31/78 (39.7%) |
| Vehicle | — | 1/79 (1.3%) | 26/79 (32.9%) |
| Event | CD1579 2.5% | CD1579 5% | Vehicle |
|---|---|---|---|
| Compression fractureInjury, poisoning and procedural complications | 0/79 | 0/78 | 1/79 |
| Event | CD1579 2.5% | CD1579 5% | Vehicle |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 10/79 | 11/78 | 11/79 |
| HeadacheNervous system disorders | 8/79 | 1/78 | 7/79 |
| DysmenorrhoeaReproductive system and breast disorders | 5/79 | 3/78 | 3/79 |
| Skin irritationSkin and subcutaneous tissue disorders | 3/79 | 1/78 | 0/79 |
| Seasonal allergyImmune system disorders | 2/79 | 2/78 | 2/79 |
| Oral herpesInfections and infestations | 1/79 | 2/78 | 0/79 |
| EczemaSkin and subcutaneous tissue disorders | 1/79 | 2/78 | 0/79 |
| UrticariaSkin and subcutaneous tissue disorders | 1/79 | 2/78 | 0/79 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 2/79 | 0/78 | 0/79 |
| Erythema of eyelidEye disorders | 1/79 | 1/78 | 0/79 |
| Age, Continuous(years) | CD1579 2.5% | CD1579 5% | Vehicle | Total |
|---|---|---|---|---|
| Mean | 22.1 ± 7.0 | 21.1 ± 5.6 | 21.0 ± 6.3 | 21.4 ± 6.3 |
| Sex: Female, Male(Participants) | CD1579 2.5% | CD1579 5% | Vehicle | Total |
|---|---|---|---|---|
| Female | 57 | 51 | 45 | 153 |
| Male | 22 | 27 | 34 | 83 |
| Region of Enrollment(participants) | CD1579 2.5% | CD1579 5% | Vehicle | Total |
|---|---|---|---|---|
| Japan | 79 | 78 | 79 | 236 |
The record gives a start of Mar 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benzoyl Peroxide